TREVENA INC (TRVN)

Company Profile

Trevena, Inc. is a biopharmaceutical company, which focuses on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders. The company is headquartered in Chesterbrook, Pennsylvania and currently employs 35 full-time employees. The company went IPO on 2014-01-31. The firm is focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The firm's product, OLINVYK (oliceridine) injection, is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The company is also engaged in three differentiated investigational drug candidates: TRV045, TRV250, and TRV734. TRV045 is a novel sphingosine-1-phosphate (S1P), receptor modulator that may offer a new, non-opioid approach to managing chronic pain, as well as treating epilepsy and seizure disorders. TRV250 is a G-protein biased delta-opioid receptor (DOR), agonist as a compound with a mechanism for the treatment of acute migraine. TRV734 is a new chemical entity (NCE) targeting the same mechanism of action at the mu-opioid receptor (MOR). TRV734 is used for the treatment of opioid use disorder.

Company Info

TREVENA INC

955 Chesterbrook Boulevard, Suite 110

Chesterbrook PENNSYLVANIA 19087

P: 16103548840

CEO: Carrie L. Bourdow

Employees: 35

Website: https://www.trevena.com/